Revvity (RVTY) is back in focus after its latest earnings report, which showed higher third quarter sales and net income, along with an upward shift in earnings estimates that prompted a Zacks Rank upgrade.
Revvity’s latest results and dividend affirmation have landed on top of a strong run. The share price is up 33.69% over the past 90 days and the year-to-date share price return is 58.03%, while the 1-year total shareholder return of 71.28% signals that momentum has been building over the past year, despite a weaker 5-year total shareholder return that is down 14.49%.
Spot 19 high quality undiscovered gems that share Revvity’s mix of earnings momentum and under-the-radar appeal before the next wave of upgrades lands.After a run to about $155 and fresh earnings momentum, the real fork in the road is timing. Is Revvity already pricing in the good news, or does the current valuation still leave meaningful room before chasing becomes a risk?
Most Popular Narrative: 1% Overvalued
The most followed narrative pegs Revvity’s fair value at $154, which sits just below the last close at $155.11. That tiny gap puts the focus squarely on whether the recent earnings strength can support the premium already reflected in the price.
The current valuation suggests that investors are already paying a premium for sustained growth in areas such as Signals software, reproductive health, and ex-China immunodiagnostics, even though the company’s longer-term revenue and EPS trends have been under pressure.
See why 11 investors see Revvity as 1% overvalued.
Result: Fair Value of $154 (OVERVALUED)
Still, if Revvity’s Signals software grows faster than modeled or reproductive health and ex China immunodiagnostics stay strong, that could challenge the view that the shares are overvalued by about 1%.
Find out about the key risks to this Revvity narrative.
Next Steps
Mixed signals around Revvity’s valuation and recent run can feel like a lot to weigh, so review the detail for yourself and decide where you stand by checking the 1 key reward and 2 important warning signs.
Looking for more investment ideas beyond Revvity?
If Revvity has sharpened your focus on quality opportunities, do not stop here. Use the Simply Wall St Screener to surface other targeted ideas that fit your plan.
- Target resilient performers that aim to limit downside risk by screening for 31 resilient stocks with low risk scores that could help smooth out a volatile portfolio.
- Hunt for strong fundamentals by zeroing in on companies with robust balance sheets and consistent financial profiles using the list of solid balance sheet and fundamentals (25 results).
- Spot potential future leaders early by scanning the 19 high quality undiscovered gems before they attract wider attention and re-rating pressure.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com